Member Info for B2HS2L

I think this is likely -
"the company think the physical launch of co prep isn't material enough to warrant an RNS"
because there are a number of more important subjects that must be RNS'd that will be ready to notify soon.
In comparison with these subjects, CO-Prep launch is not material enough.
++++
- but it probably would be if it were the case that Novacyt released the number of pre-launch orders that have been taken, and what these were worth.

That wouldn't be an 'R&D update' tomorrow, - complete with CO-Prep market launch details?
That would buoy the sp.
We must be due one, else everything comes at end of April :(

Quick question InvSteve -
Are you talking about pre October 18th facts?
Does it seem that DA is doing on twitter what GM did via RNS.
And if so how much does that matter?

A recent TATA video showed a diagram of Q32 machines operating as a network from a laptop.
I assume each networked instrument would need a CO-Prep cabinet.
That is the kind of scenario that might increasingly be discussed within customer labs, if a new more dangerous vaccine evasive variant was to appear.
So why don't we see a video of that from Novacyt.
It would show multiple samples being processed in batches of 30 per instrument.
It would let the Greyhound see the Hare and plant a few ideas out there.
If our lab isn't doing this, who else is? - it's capability each lab would need worse case.

Agreed - but it's now on twitter
https://twitter.com/NovacytGroup/status/1504018659446079489

Careful HarChris, -
You make it sound like he's selling perfume.
Most of this year this share has been represented by Disney's skunk character Pepe le pew.
Not any longer though.

For interest:

https://novacyt.com/aim-rule-26/#aim-takeover

"Novacyt takeover code

The Company is not subject to the UK City Code on Takeovers and Mergers. However, French law contains provisions relating to takeovers of certain companies, including the Company.
The General Regulation of the Autorité Des Marchés Financiers of France (the AMF) applies to the Company, as it is a public limited company whose shares were first admitted to trading on Euronext Growth Paris, if an acquisition of shares in such a company were to increase the aggregate holding of the acquirer and its concert parties to interests in shares carrying 50 per cent. or more of the share capital or voting rights in the company, the acquirer and its concert parties would be required (except with the consent of the AMF) to make a cash offer for the outstanding shares at a price not less than the highest price paid for the shares by the acquirer or its concert parties during the previous twelve months."

HKK -

F) None of the above *

* Leak's are not something Novacyt does.

Guillermo Raimondo next or I'll eat my hat.

sp rises on buying interest from a competitor.
DHSC dispute is settled, and blows the share buying programme of the interested party out of the water..
You've gotta larf, - it could happen.

Was expecting a TR1 today Chris

Resurrect plan A&B, or we're off to hell in a handcart ye ken.
We're all doomed I tellye ... we're everyoneofus dooooomed!!

New to UJO, so unsure if the possibility that future fracking will occur is the planning authority's number one concern.
However assuming Fracking is a major issue, why could they not provide conditional approval, the proviso being that no future fracking activity must occur?
What do others feel, - how likely is that?

Monty -
From 25.01 RNS "The Company intends to announce its 2021 audited full year results in the week commencing 25 April 2022"

In the same boat Bloodshot.

If not Biosynex then another opportunity will be along soon.

EXMEX, - I read your post and it posed these questions for me:
1 Is it in the best interests of Biosynex to listen to a Novacyt strategy reveal? - Does that beg the question that if Bio are serious about a buyout, it needs to be done before said reveal takes place, so that any strategy announced is that of the new owner?

2 We cannot know if a seat on the board completes Biosynex's share buying operation, without observing if share buying continues after the seat is offered and accepted. - Better offer it sooner rather than later then, say 10%?

3 One form of defence (if the approach is not welcome) is to release share price sensitive information, not previously made available.
The BoD might not want to do this, - but needs must.

Another form of defence is to bring forward the bulk of the strategy announcement, announcing the rest when it is available. - If your going to announce it, do it sooner. Word it so it strengthens the sp.

++++
18.11.2021 - Biosynex statement of intent.
https://www.degaullefleurance.com/en/financement-syndique-de-biosynex-de-gaulle-fleurance-associes-a-conseille-la-caisse-depargne-grand-est-europe-et-les-autres-preteurs/

"syndicated loan facility for a maximum amount of €109 million.

This transaction was arranged by Caisse d’Epargne Grand-Est Europe, advised by De Gaulle Fleurance & Associés.
Through this financing, BIOSYNEX plans to secure the Group’s general needs and pursue its external acquisitions with the ambition of becoming the European leader in the field of rapid POC (“Point Of Care”) diagnostics."

"These acquisitions are intended to build up a portfolio of synergistic and complementary technologies in molecular biology and in point-of-care. In addition, the Group intends to accelerate its international development through the consolidation of its distributors and the creation of new subsidiaries."

We can be an active willing partner in this statement of intent, or we can be an important milestone acquisition in Biosynex's pursuit of it. Recall Biosynex have LFT manufacturing facilities.

What choices have our BoD made so far?
There is no defences being erected, and as kaeren states, a hostile takeover is unlikely.
So are we expecting BoD to eventually be recommending a takeover in the future, in which case we won't need a strategy announcement based on Allmond's thoughts, because we will have one from Biosynex?

From David's only video
"09:52 We started out very reliant on the UK, we still do a lot of business in the UK, but the clearest opportunity for us is to leverage our CE marked products across the European economic area, so a huge area for which we already have regulatory coverage."

Have we to wait until April for Davids strategy revue that will contain reference to a joint strategy with Biosynex?
That's would be why we have to wait until April, to allow the ducks to align?

IMO the worldwide testing industry is very fragmented and awaits much M&A action.
If no

Here's what Mandy had to say when discussing the timing of the TR-1 this morning:

"No significance – we have a strict approval process to follow involving teams in both France and the UK before RNS are issued and we only received the TR1 at COB yesterday."

If both armies contracted the latest variant, that really would bring 'War of the Worlds' to life.

Well BoD might be in the market to purchase their own shares ?